ווטריינט 400 מ"ג

Pajjiż: Iżrael

Lingwa: Ebrajk

Sors: Ministry of Health

Ingredjent attiv:

PAZOPANIB AS HYDROCHLORIDE 400 MG

Disponibbli minn:

GLAXO SMITH KLINE (ISRAEL) LTD

Kodiċi ATC:

L01XE11

Għamla farmaċewtika:

FILM COATED TABLETS

Rotta amministrattiva:

PER OS

Manifatturat minn:

GLAXO OPERATIONS UK LIMITED

Grupp terapewtiku:

PAZOPANIB

Indikazzjonijiet terapewtiċi:

Renal cell carcinoma (RCC)Votrient is indicated in adults for the first line treatment of advanced Renal Cell Carcinoma (RCC) and for patients who have received prior cytokine therapy for advanced disease.Soft tissue sarcoma (STS)Votrient is indicated for the treatment of adult patients with selective subtypes of advanced Soft Tissue Sarcoma (STS) who have received prior chemotherapy for metastatic disease or who have progressed within 12 months after (neo) adjuvant therapy.

Data ta 'l-awtorizzazzjoni:

2011-01-01